Polyneuron Pharmaceuticals AG logo

Polyneuron Pharmaceuticals AG

Swiss biotech start-up. We?re using our Antibody-Catch? technology to develop accurate treatments for rare autoimmune disorders. Polyneuron is an early stage Swiss pharmaceutical company (spin-off from the University of Basel) is developing antibodies targeting autoimmune diseases of the peripheral nervous system.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://polyneuron.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Basel Inkubator Hochbergerstrasse 60 CCH-4057
Basel
Switzerland
Email
Contact Number
+41 78 837 10 11

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/polyneuron-pharmaceuticals” connections=”true” suffix=””]

Polyneurons Antibody-Catchë platform technology enables the development of antibody-specific immunotherapy for autoimmune diseases involving antibodies against glyco-epitopes.

May 2018, Polyneurons completes CHF 3.1 M seed financing. The financing was led by EVA Basel and included the ZÈrcher Kantonalbank and private investors.

In Jun 2015, Polyneuron received 130,000 francs as a starting capital from Venture Kick.